|
1
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun
Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ji MF, Sheng W, Cheng WM, Ng MH, Wu BH, Yu
X, Wei KR, Li FG, Lian SF, Wang PP, et al: Incidence and mortality
of nasopharyngeal carcinoma: Interim analysis of a cluster
randomized controlled screening trial (PRO-NPC-001) in southern
China. Ann Oncol. 30:1630–1637. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaidar-Person O, Gil Z and Billan S:
Precision medicine in head and neck cancer. Drug Resist Updat.
40:13–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Madani Tonekaboni SA, Soltan Ghoraie L,
Manem VSK and Haibe-Kains B: Predictive approaches for drug
combination discovery in cancer. Brief Bioinform. 19:263–276. 2018.
View Article : Google Scholar :
|
|
6
|
Wong AS, Soo RA, Lu JJ, Loh KS, Tan KS,
Hsieh WS, Shakespeare TP, Chua ET, Lim HL and Goh BC: Paclitaxel,
5-fluorouracil and hydroxyurea concurrent with radiation in locally
advanced nasopharyngeal carcinoma. Ann Oncol. 17:1152–1157. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott K, Hayden PJ, Will A, Wheatley K and
Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane
Database Syst Rev. 4:CD0108162016.PubMed/NCBI
|
|
8
|
Davies AM, Lara PN Jr, Mack PC and Gandara
DR: Incorporating bortezomib into the treatment of lung cancer.
Clin Cancer Res. 13:s4647–4651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang IT, Dhungel B, Shrestha R, Bridle
KR, Crawford DHG, Jayachandran A and Steel JC: Spotlight on
Bortezomib: Potential in the treatment of hepatocellular carcinoma.
Expert Opin Investig Drugs. 28:7–18. 2019. View Article : Google Scholar
|
|
10
|
Ri M: Endoplasmic-reticulum stress
pathway-associated mechanisms of action of proteasome inhibitors in
multiple myeloma. Int J Hematol. 104:273–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manasanch EE and Orlowski RZ: Proteasome
inhibitors in cancer therapy. Nat Rev Clin Oncol. 14:417–433. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hochstrasser M: Ubiquitin, proteasomes,
and the regulation of intracellular protein degradation. Curr Opin
Cell Biol. 7:215–223. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Skaar JR and Pagano M: Control of cell
growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol.
21:816–824. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joerger M: Treatment regimens of classical
and newer taxanes. Cancer Chemother Pharmacol. 77:221–233. 2016.
View Article : Google Scholar
|
|
15
|
Alushin GM, Lander GC, Kellogg EH, Zhang
R, Baker D and Nogales E: High-resolution microtubule structures
reveal the structural transitions in alphabeta-tubulin upon GTP
hydrolysis. Cell. 157:1117–1129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi X and Sun X: Regulation of paclitaxel
activity by microtubule-associated proteins in cancer chemotherapy.
Cancer Chemother Pharmacol. 80:909–917. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vitale I, Galluzzi L, Castedo M and
Kroemer G: Mitotic catastrophe: A mechanism for avoiding genomic
instability. Nat Rev Mol Cell Biol. 12:385–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roninson IB, Broude EV and Chang BD: If
not apoptosis, then what? Treatment-induced senescence and mitotic
catastrophe in tumor cells. Drug Resist Updat. 4:303–313. 2001.
View Article : Google Scholar
|
|
20
|
Castedo M, Perfettini JL, Roumier T,
Andreau K, Medema R and Kroemer G: Cell death by mitotic
catastrophe: A molecular definition. Oncogene. 23:2825–2837. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Denisenko TV, Sorokina IV, Gogvadze V and
Zhivotovsky B: Mitotic catastrophe and cancer drug resistance: A
link that must to be broken. Drug Resist Updat. 24:1–12. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi J and Mitchison TJ: Cell death
response to anti-mitotic drug treatment in cell culture, mouse
tumor model and the clinic. Endocr Relat Cancer. 24:T83–T96. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brito DA and Rieder CL: Mitotic checkpoint
slippage in humans occurs via cyclin B destruction in the presence
of an active checkpoint. Curr Biol. 16:1194–1200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mc Gee MM: Targeting the mitotic
catastrophe signaling pathway in cancer. Mediators Inflamm.
2015:1462822015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fung TK and Poon RY: A roller coaster ride
with the mitotic cyclins. Semin Cell Dev Biol. 16:335–342. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kalous J, Jansova D and Susor A: Role of
cyclin-dependent kinase 1 in translational regulation in the
M-Phase. Cells. 9:15682020. View Article : Google Scholar :
|
|
27
|
Yang J, Bardes ES, Moore JD, Brennan J,
Powers MA and Kornbluth S: Control of cyclin B1 localization
through regulated binding of the nuclear export factor CRM1. Genes
Dev. 12:2131–2143. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coulonval K, Kooken H and Roger PP:
Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1
from premature activation. Mol Biol Cell. 22:3971–3985. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lindqvist A, Rodriguez-Bravo V and Medema
RH: The decision to enter mitosis: Feedback and redundancy in the
mitotic entry network. J Cell Biol. 185:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sinha D, Duijf PHG and Khanna KK: Mitotic
slippage: An old tale with a new twist. Cell cycle. 18:7–15. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mascaraque M, Delgado-Wicke P, Damian A,
Lucena SR, Carrasco E and Juarranz A: Mitotic catastrophe induced
in HeLa tumor cells by photodynamic therapy with
methyl-aminolevulinate. Int J Mol Sci. 20:12292019. View Article : Google Scholar :
|
|
32
|
Vakifahmetoglu H, Olsson M and Zhivotovsky
B: Death through a tragedy: Mitotic catastrophe. Cell Death Differ.
15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Orth JD, Kohler RH, Foijer F, Sorger PK,
Weissleder R and Mitchison TJ: Analysis of mitosis and antimitotic
drug responses in tumors by in vivo microscopy and single-cell
pharmacodynamics. Cancer Res. 71:4608–4616. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jackman M, Kubota Y, den Elzen N, Hagting
A and Pines J: Cyclin A- and cyclin E-Cdk complexes shuttle between
the nucleus and the cytoplasm. Mol Biol Cell. 13:1030–1045. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Harashima H, Dissmeyer N and Schnittger A:
Cell cycle control across the eukaryotic kingdom. Trends Cell Biol.
23:345–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vassilev LT, Tovar C, Chen S, Knezevic D,
Zhao X, Sun H, Heimbrook DC and Chen L: Selective small-molecule
inhibitor reveals critical mitotic functions of human CDK1. Proc
Natl Acad Sci USA. 103:10660–10665. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Steg AD, Burke MR, Amm HM, Katre AA,
Dobbin ZC, Jeong DH and Landen CN: Proteasome inhibition reverses
hedgehog inhibitor and taxane resistance in ovarian cancer.
Oncotarget. 5:7065–7080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan TT, Degenhardt K, Nelson DA, Beau B,
Nieves-Neira W, Bouillet P, Villunger A, Adams JM and White E: Key
roles of BIM-driven apoptosis in epithelial tumors and rational
chemotherapy. Cancer Cell. 7:227–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Edelman MJ, Burrows W, Krasna MJ, Bedor M,
Smith R and Suntharalingam M: Phase I trial of
carboplatin/paclitaxel/bortezomib and concurrent radiotherapy
followed by surgical resection in Stage III non-small cell lung
cancer. Lung cancer. 68:84–88. 2010. View Article : Google Scholar
|
|
40
|
Jatoi A, Dakhil SR, Foster NR, Ma C,
Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD,
Flynn PJ, et al: Bortezomib, paclitaxel, and carboplatin as a
first-line regimen for patients with metastatic esophageal,
gastric, and gastroesophageal cancer: Phase II results from the
North Central Cancer Treatment Group (N044B). J Thorac Oncol.
3:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Croghan GA, Suman VJ, Maples WJ, Albertini
M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN and
Erlichman C: A study of paclitaxel, carboplatin, and bortezomib in
the treatment of metastatic malignant melanoma: A phase 2
consortium study. Cancer. 116:3463–3468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cresta S, Sessa C, Catapano CV, Gallerani
E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, Maur M, Capri G,
et al: Phase I study of bortezomib with weekly paclitaxel in
patients with advanced solid tumours. Eur J Cancer. 44:1829–1834.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mehnert JM, Tan AR, Moss R, Poplin E,
Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, et al:
Rationally designed treatment for solid tumors with MAPK pathway
activation: A phase I study of paclitaxel and bortezomib using an
adaptive dose-finding approach. Mol Cancer Ther. 10:1509–1519.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ramaswamy B, Bekaii-Saab T, Schaaf LJ,
Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K,
Wilkins D, et al: A dose-finding and pharmacodynamic study of
bortezomib in combination with weekly paclitaxel in patients with
advanced solid tumors. Cancer Chemother Pharmacol. 66:151–158.
2010. View Article : Google Scholar
|
|
45
|
Zhao Y, Foster NR, Meyers JP, Thomas SP,
Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR,
Mandrekar SJ, et al: A phase I/II study of bortezomib in
combination with paclitaxel, carboplatin, and concurrent thoracic
radiation therapy for non-small-cell lung cancer: North Central
Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 10:172–180.
2015. View Article : Google Scholar :
|
|
46
|
Ma C, Mandrekar SJ, Alberts SR, Croghan
GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, et al:
A phase I and pharmacologic study of sequences of the proteasome
inhibitor, bortezomib (PS-341, Velcade), in combination with
paclitaxel and carboplatin in patients with advanced malignancies.
Cancer Chemother Pharmacol. 59:207–215. 2007. View Article : Google Scholar
|
|
47
|
Castedo M, Perfettini JL, Roumier T and
Kroemer G: Cyclin-dependent kinase-1: Linking apoptosis to cell
cycle and mitotic catastrophe. Cell Death Differ. 9:1287–1293.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sakurikar N, Eichhorn JM and Chambers TC:
Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after
mitotic arrest via phosphoregulation of antiapoptotic Bcl-2
proteins. J Biol Chem. 287:39193–39204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hou Y, Allan LA and Clarke PR:
Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell
death. J Cell Sci. 130:502–511. 2017.
|
|
50
|
Harley ME, Allan LA, Sanderson HS and
Clarke PR: Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its
Cdc20-dependent destruction during mitotic arrest. The EMBO J.
29:2407–2420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Allan LA and Clarke PR: Phosphorylation of
caspase-9 by CDK1/cyclin B1 protects mitotic cells against
apoptosis. Mol Cell. 26:301–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Clarke PR and Allan LA: Destruction's our
delight: Controlling apoptosis during mitotic arrest. Cell Cycle.
9:4035–4036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lu Z and Hunter T: Ubiquitylation and
proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2)
CDK inhibitors. Cell Cycle. 9:2342–2352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Millman SE and Pagano M: MCL1 meets its
end during mitotic arrest. EMBO Rep. 12:384–385. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kreis NN, Louwen F and Yuan J: Less
understood issues: p21(Cip1) in mitosis and its therapeutic
potential. Oncogene. 34:1758–1767. 2015. View Article : Google Scholar
|
|
56
|
Gavet O and Pines J: Progressive
activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell.
18:533–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rata S, Suarez Peredo Rodriguez MF, Joseph
S, Peter N, Echegaray Iturra F, Yang F, Madzvamuse A, Ruppert JG,
Samejima K, Platani M, et al: Two interlinked bistable switches
govern mitotic control in mammalian cells. Curr Biol. 28:3824–3832
e3826. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Diril MK, Ratnacaram CK, Padmakumar VC, Du
T, Wasser M, Coppola V, Tessarollo L and Kaldis P: Cyclin-dependent
kinase 1 (Cdk1) is essential for cell division and suppression of
DNA re-replication but not for liver regeneration. Proc Natl Acad
Sci USA. 109:3826–3831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Saito M, Mulati M, Talib SZ, Kaldis P,
Takeda S, Okawa A and Inose H: The indispensable role of
cyclin-dependent kinase 1 in skeletal development. Sci Rep.
6:206222016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Soni DV, Sramkoski RM, Lam M, Stefan T and
Jacobberger JW: Cyclin B1 is rate limiting but not essential for
mitotic entry and progression in mammalian somatic cells. Cell
Cycle. 7:1285–1300. 2008. View Article : Google Scholar : PubMed/NCBI
|
